Diego Villa

7.4k total citations
147 papers, 2.5k citations indexed

About

Diego Villa is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Diego Villa has authored 147 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Pathology and Forensic Medicine, 58 papers in Oncology and 50 papers in Genetics. Recurrent topics in Diego Villa's work include Lymphoma Diagnosis and Treatment (113 papers), CNS Lymphoma Diagnosis and Treatment (42 papers) and Chronic Lymphocytic Leukemia Research (39 papers). Diego Villa is often cited by papers focused on Lymphoma Diagnosis and Treatment (113 papers), CNS Lymphoma Diagnosis and Treatment (42 papers) and Chronic Lymphocytic Leukemia Research (39 papers). Diego Villa collaborates with scholars based in Canada, United States and Denmark. Diego Villa's co-authors include Kerry J. Savage, Laurie H. Sehn, Joseph M. Connors, Randy D. Gascoyne, Tamara Shenkier, Richard Klasa, David W. Scott, Alina S. Gerrie, Graham W. Slack and Tarec Christoffer El‐Galaly and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Diego Villa

128 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diego Villa Canada	26	2.0k	1.2k	987	721	334	147	2.5k
Hervé Ghesquières France	31	2.1k 1.1×	1.6k 1.3×	877 0.9×	852 1.2×	274 0.8×	193	3.0k
Vincent Delwail France	23	2.1k 1.0×	1.1k 0.9×	1.1k 1.2×	1.3k 1.8×	168 0.5×	78	2.6k
Karamjit Gill Canada	13	2.4k 1.2×	1.6k 1.3×	636 0.6×	859 1.2×	292 0.9×	19	2.9k
Annarita Conconi Italy	24	1.9k 0.9×	1.0k 0.8×	550 0.6×	701 1.0×	386 1.2×	71	2.3k
Emilio Iannitto Italy	29	2.4k 1.2×	1.3k 1.1×	679 0.7×	916 1.3×	637 1.9×	78	3.5k
Monica Tani Italy	26	1.7k 0.8×	819 0.7×	509 0.5×	453 0.6×	385 1.2×	105	2.2k
Pauline Brice France	23	2.3k 1.1×	1.4k 1.1×	722 0.7×	546 0.8×	467 1.4×	75	3.1k
Vittorio Stefoni Italy	30	2.3k 1.1×	958 0.8×	709 0.7×	609 0.8×	589 1.8×	133	2.8k
Pierre Feugier France	26	3.2k 1.6×	2.2k 1.8×	876 0.9×	1.4k 1.9×	335 1.0×	79	3.8k
Max Wolf Australia	22	1.7k 0.8×	1.0k 0.9×	490 0.5×	791 1.1×	275 0.8×	55	2.1k

Countries citing papers authored by Diego Villa

Since Specialization

Citations

This map shows the geographic impact of Diego Villa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diego Villa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diego Villa more than expected).

Fields of papers citing papers by Diego Villa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diego Villa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diego Villa. The network helps show where Diego Villa may publish in the future.

Co-authorship network of co-authors of Diego Villa

This figure shows the co-authorship network connecting the top 25 collaborators of Diego Villa. A scholar is included among the top collaborators of Diego Villa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diego Villa. Diego Villa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meric‐Bernstam, Funda, Martin Gutierrez, Enrique Sanz‐García, et al.. (2025). Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications. 5(9). 1664–1673. 1 indexed citations

Villa, Diego, Jean-François Larouche, Matthew C. Cheung, et al.. (2023). Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial. Hematological Oncology. 41(S2). 483–484.

Villa, Diego, Jean-François Larouche, Matthew C. Cheung, et al.. (2023). Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial. Blood. 142(Supplement 1). 3042–3042.

Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585. 11 indexed citations

Gerrie, Alina S., Kerry J. Savage, Diego Villa, et al.. (2023). Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis. Leukemia & lymphoma. 65(3). 346–352. 2 indexed citations

Berinstein, Neil L., Kees-Peter de Roos, Rebecca F. McClure, et al.. (2023). Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM). Hematological Oncology. 41(S2). 396–397. 1 indexed citations

Kwon, Daniel, Katsuyoshi Takata, Zhengxing Zhang, et al.. (2022). Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. Clinical Cancer Research. 28(8). 1628–1639. 8 indexed citations

El‐Galaly, Tarec Christoffer, Diego Villa, Chan Y. Cheah, & Lars Christian Gormsen. (2022). Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?. British Journal of Haematology. 197(2). 139–155. 17 indexed citations

Villa, Diego, Ciara L. Freeman, Graham W. Slack, et al.. (2022). Clinicopathological characteristics and long‐term outcomes of plasmablastic lymphoma in British Columbia. British Journal of Haematology. 199(2). 230–238. 6 indexed citations

10.

El‐Galaly, Tarec Christoffer, Chan Y. Cheah, & Diego Villa. (2019). Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. British Journal of Haematology. 186(3). 409–419. 5 indexed citations

11.

Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances. 3(13). 2013–2021. 28 indexed citations

12.

Steiner, Raphaël, Chelsea C. Pinnix, Bouthaina S. Dabaja, et al.. (2019). An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Medicine. 9(2). 663–670. 16 indexed citations

13.

Collinge, Brett, Lauren C. Chong, Susana Ben‐Neriah, et al.. (2017). Deciphering Discordance between MYC mRNA and MYC IHC in DLBCL: The Role of MYC Exon 2 Mutations and N11S Polymorphism. Blood. 130. 3994–3994. 1 indexed citations

14.

Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2017). Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study. Blood. 130. 415–415.

15.

Tsang, Erica S., Diego Villa, Federica Loscocco, et al.. (2017). Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood. 130. 3291–3291. 1 indexed citations

16.

Abrisqueta, Pau, David W. Scott, Graham W. Slack, et al.. (2017). Observation as the initial management strategy in patients with mantle cell lymphoma. Annals of Oncology. 28(10). 2489–2495. 51 indexed citations

17.

Savage, Kerry J., Samira Zeynalova, Roopesh Kansara, et al.. (2014). Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. Blood. 124(21). 394–394. 19 indexed citations

18.

Mak, Vivien, Mukesh Chhanabhai, Tamara Shenkier, et al.. (2013). Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. Journal of Clinical Oncology. 31(16). 1970–1976. 286 indexed citations

19.

Connors, Joseph M., Laurie H. Sehn, Diego Villa, et al.. (2013). Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma. Blood. 122(21). 4345–4345. 3 indexed citations

20.

Bradley, Katherine, Scott Tyldesley, Caroline Speers, Ryan Woods, & Diego Villa. (2013). Contemporary Systemic Therapy for Male Breast Cancer. Clinical Breast Cancer. 14(1). 31–39. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact